Aptamer-free upconversion nanoparticle/silk biosensor system for low-cost and highly sensitive detection of antibiotic residues
This study introduces a low-cost, eco-friendly, and highly sensitive method for antibiotic detection, with broad potential for future applications in environmental, healthcare, and food-related fields.PMID:38710144 | DOI:10.1016/j.bios.2024.116335 (Source: Biosensors and Bioelectronics)
Source: Biosensors and Bioelectronics - May 6, 2024 Category: Biotechnology Authors: Yajun Shuai Na Li Ying Zhang Qing Bao Tiancheng Wei Tao Yang Qichao Cheng Wei Wang Baolan Hu Chuanbin Mao Mingying Yang Source Type: research

Aptamer-free upconversion nanoparticle/silk biosensor system for low-cost and highly sensitive detection of antibiotic residues
This study introduces a low-cost, eco-friendly, and highly sensitive method for antibiotic detection, with broad potential for future applications in environmental, healthcare, and food-related fields.PMID:38710144 | DOI:10.1016/j.bios.2024.116335 (Source: Biosensors and Bioelectronics)
Source: Biosensors and Bioelectronics - May 6, 2024 Category: Biotechnology Authors: Yajun Shuai Na Li Ying Zhang Qing Bao Tiancheng Wei Tao Yang Qichao Cheng Wei Wang Baolan Hu Chuanbin Mao Mingying Yang Source Type: research

Prolonged mass azithromycin distributions and macrolide resistance determinants among preschool children in Niger: A sub-study of a cluster-randomized trial (MORDOR)
by Ahmed M. Arzika, Amza Abdou, Ramatou Maliki, Nassirou Beido, Boubacar Kadri, Abdoul N. Harouna, Abdoul N. Galo, Mankara K. Alio, Elodie Lebas, Catherine E. Oldenburg, Kieran S. O ’Brien, Cindi Chen, Lina Zhong, Zhaoxia Zhou, Daisy Yan, Armin Hinterwirth, Jeremy D. Keenan, Travis C. Porco, Thomas M. Lietman, Thuy Doan, for the MORDOR Study Group BackgroundRandomized controlled trials found that twice-yearly mass azithromycin administration (MDA) reduces childhood mortality, presumably by reducing infection burden. World Health Organization (WHO) issued conditional guidelines for mass azithromycin administration in high...
Source: PLoS Medicine - May 6, 2024 Category: Internal Medicine Authors: Ahmed M. Arzika Source Type: research

Azithromycin removal using pine bark, oak ash and mussel shell
Environ Res. 2024 Apr 30:119048. doi: 10.1016/j.envres.2024.119048. Online ahead of print.ABSTRACTAdsorption is considered an interesting option for removing antibiotics from the environment because of its simple design, low cost, and potential efficiency. In this work we evaluated three by-products (pine bark, oak ash, and mussel shell) as bio-adsorbents for the antibiotic azithromycin (AZM). Furthermore, they were added at doses of 48 t ha-1 to four different soils, then comparing AZM removal for soils with and without bio-adsorbents. Batch-type experiments were used, adding AZM concentrations between 2.5 and 600 μmol L...
Source: Environmental Research - May 2, 2024 Category: Environmental Health Authors: Raquel Cela-Dablanca Ana Barreiro Luc ía Rodríguez-López Manuel Arias-Est évez Mar ía Fernández-Sanjurjo Esperanza Álvarez-Rodríguez Avelino N úñez-Delgado Source Type: research

Azithromycin removal using pine bark, oak ash and mussel shell
Environ Res. 2024 Apr 30:119048. doi: 10.1016/j.envres.2024.119048. Online ahead of print.ABSTRACTAdsorption is considered an interesting option for removing antibiotics from the environment because of its simple design, low cost, and potential efficiency. In this work we evaluated three by-products (pine bark, oak ash, and mussel shell) as bio-adsorbents for the antibiotic azithromycin (AZM). Furthermore, they were added at doses of 48 t ha-1 to four different soils, then comparing AZM removal for soils with and without bio-adsorbents. Batch-type experiments were used, adding AZM concentrations between 2.5 and 600 μmol L...
Source: Environmental Research - May 2, 2024 Category: Environmental Health Authors: Raquel Cela-Dablanca Ana Barreiro Luc ía Rodríguez-López Manuel Arias-Est évez Mar ía Fernández-Sanjurjo Esperanza Álvarez-Rodríguez Avelino N úñez-Delgado Source Type: research

Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint
Extract Current rifampicin/ethambutol/azithromycin regimens for the treatment of Mycobacterium avium complex pulmonary disease (MAC-PD) are long, toxic and yield relatively poor outcomes [1]: a meta-analysis lumping nodular bronchiectatic disease and fibro-cavitary disease reported a 65% prolonged culture conversion rate; following initially successful treatment, recurrence rates of 30% have been reported [2]. (Source: European Respiratory Journal)
Source: European Respiratory Journal - May 2, 2024 Category: Respiratory Medicine Authors: van Ingen, J., Hoefsloot, W., Dartois, V., Dick, T. Tags: Editorials Source Type: research

Antimicrobial susceptibility testing reveals reduced susceptibility to azithromycin and other antibiotics in Legionella pneumophila serogroup 1 isolates from Portugal
ConclusionsWe report, for the first time, elevated MICs against first-line and other antibiotics (including azithromycin, fluoroquinolones and amoxicillin/clavulanic acid commonly used to treat pneumonia patients in Portugal) in PortugueseL. pneumophila strains. Results point towards decreased susceptibility in circulating strains, justifying further investigation. (Source: European Journal of Clinical Microbiology and Infectious Diseases)
Source: European Journal of Clinical Microbiology and Infectious Diseases - May 2, 2024 Category: Microbiology Source Type: research

Could the effect of antimicrobials on antimicrobial resistance be saturated at high antimicrobial consumption? A comparison of the MORDOR and ResistAZM studies
Numerous studies have confirmed the association between antimicrobial use and antimicrobial resistance (AMR), pheno- or genotypically [1]. One such study, the MORDOR trial, showed a 7-fold increase in the abundance of macrolide resistance genes in preschool children in Niger following azithromycin mass distribution that reduced childhood mortality [2,3]. In another study, a single course of antibiotic (1.5 g of azithromycin) increased the proportion of oral streptococci with macrolide resistance from 30% to 80% [4]. (Source: International Journal of Infectious Diseases)
Source: International Journal of Infectious Diseases - May 2, 2024 Category: Infectious Diseases Authors: Sheeba Santhini Manoharan-Basil, Zina Gestels, Sa ïd Abdelatti, Irith De Baetselier, Thibaut Vanbaelen, Armin Hinterwirth, Thuy Doan, Thomas Lietman, Chris Kenyon Tags: Short Communication Source Type: research

Treatment of peri-implantitis with a flapless surgical access combined with implant surface decontamination and adjunctive systemic antibiotics: A retrospective case series study
CONCLUSIONS: A flapless surgical approach led to disease resolution in 54.4% of the implants with peri-implantitis. Several risk/protective predictors for disease resolution were identified.PMID:38690660 | DOI:10.1111/jcpe.13993 (Source: Journal of Clinical Periodontology)
Source: Journal of Clinical Periodontology - May 1, 2024 Category: Dentistry Authors: Ana Carrillo de Albornoz Eduardo Montero Andrea Alonso-Espa ñol Mariano Sanz Ignacio Sanz-S ánchez Source Type: research

Treatment of peri-implantitis with a flapless surgical access combined with implant surface decontamination and adjunctive systemic antibiotics: A retrospective case series study
CONCLUSIONS: A flapless surgical approach led to disease resolution in 54.4% of the implants with peri-implantitis. Several risk/protective predictors for disease resolution were identified.PMID:38690660 | DOI:10.1111/jcpe.13993 (Source: Journal of Clinical Periodontology)
Source: Journal of Clinical Periodontology - May 1, 2024 Category: Dentistry Authors: Ana Carrillo de Albornoz Eduardo Montero Andrea Alonso-Espa ñol Mariano Sanz Ignacio Sanz-S ánchez Source Type: research

Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial
Lancet Respir Med. 2024 Apr 25:S2213-2600(24)00079-1. doi: 10.1016/S2213-2600(24)00079-1. Online ahead of print.ABSTRACTBACKGROUND: Systematic reviews have reported conflicting evidence on whether macrolide antibiotics reduce rates of chronic lung disease of prematurity (CLD) in at-risk preterm infants born at less than 30 weeks' gestation, including in those colonised with pulmonary Ureaplasma spp. Since an adequately powered trial has been lacking, we aimed to assess if the macrolide azithromycin improved survival without the development of physiologically defined moderate or severe CLD in preterm infants.METHODS: AZTEC ...
Source: Respiratory Care - April 28, 2024 Category: Respiratory Medicine Authors: John Lowe David Gillespie Ali Aboklaish Tin Man Mandy Lau Claudia Consoli Malavika Babu Mark Goddard Kerenza Hood Nigel Klein Emma Thomas-Jones Mark Turner Marie Hubbard Julian Marchesi Janet Berrington Sailesh Kotecha Source Type: research

Detection of OXA-181 Carbapenemase in Shigella flexneri
We report the detection of OXA-181 carbapenemase in an azithromycin-resistant Shigella spp. bacteria in an immunocompromised patient. The emergence of OXA-181 in Shigella spp. bacteria raises concerns about the global dissemination of carbapenem resistance in Enterobacterales and its implications for the treatment of infections caused by Shigella bacteria.PMID:38666725 | DOI:10.3201/eid3005.231558 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - April 26, 2024 Category: Infectious Diseases Authors: Ghulam Dhabaan Hassan Jamal Danielle Ouellette Sarah Alexander Karen Arane Aaron Campigotto Manal Tadros Pierre-Philippe Pich é-Renaud Source Type: research

Detection of OXA-181 Carbapenemase in Shigella flexneri
We report the detection of OXA-181 carbapenemase in an azithromycin-resistant Shigella spp. bacteria in an immunocompromised patient. The emergence of OXA-181 in Shigella spp. bacteria raises concerns about the global dissemination of carbapenem resistance in Enterobacterales and its implications for the treatment of infections caused by Shigella bacteria.PMID:38666725 | DOI:10.3201/eid3005.231558 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - April 26, 2024 Category: Infectious Diseases Authors: Ghulam Dhabaan Hassan Jamal Danielle Ouellette Sarah Alexander Karen Arane Aaron Campigotto Manal Tadros Pierre-Philippe Pich é-Renaud Source Type: research

Detection of OXA-181 Carbapenemase in Shigella flexneri
We report the detection of OXA-181 carbapenemase in an azithromycin-resistant Shigella spp. bacteria in an immunocompromised patient. The emergence of OXA-181 in Shigella spp. bacteria raises concerns about the global dissemination of carbapenem resistance in Enterobacterales and its implications for the treatment of infections caused by Shigella bacteria.PMID:38666725 | DOI:10.3201/eid3005.231558 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - April 26, 2024 Category: Infectious Diseases Authors: Ghulam Dhabaan Hassan Jamal Danielle Ouellette Sarah Alexander Karen Arane Aaron Campigotto Manal Tadros Pierre-Philippe Pich é-Renaud Source Type: research